Fasoracetam

—

evidence score

nootropic

Gray Market

NS-105LAM-105NFC-1+1 more

Fasoracetam is a novel racetam that reached Phase III trials (NFC-1) for ADHD in adolescents with glutamatergic gene variants — making it unique as the only racetam with substantial Phase III clinical data. Its mechanism differs from older racetams: it upregulates and restores mGluR (metabotropic glutamate receptor) density that has been downregulated by excessive stimulant use or glutamatergic dysfunction. This makes it particularly useful for preventing or reversing tolerance to ADHD medications and racetam tolerance. Also acts on GABA-B receptors (anxiolytic). More potent per milligram than piracetam. No approved medical use in US; available as research chemical.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

30 mg

15 mgRange100 mg

Frequency1-3x/day

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~1-2 hours

OnsetAcute anti-anxiety effects within 30-60 min; mGluR restoration days to weeks

DurationmGluR upregulation builds with consistent use; effects present during supplementation

Routes

oral

sublingual

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Fasoracetam is currently categorized as a nootropic compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Upregulates mGluR2/3 (Group II metabotropic glutamate receptors); GABA-B receptor agonism (anxiolytic); choline uptake facilitation; reverses mGluR downregulation from stimulant use

Practical Context

Strongest current signals

No indexed study summaries yet.